Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect
This article first appeared on GuruFocus.
Cytokinetics Inc (NASDAQ:CYTK) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $0.00 billion, and the earnings are expected to come in at -$1.57 per share. The full year 2025's revenue is expected to be $0.08 billion and the earnings are expected to be -$5.65 per share. More detailed estimate data can be found on the Forecast page.
Warning! GuruFocus has detected 9 Warning Signs with CYTK.
Is CYTK fairly valued? Test your thesis with our free DCF calculator.
Over the past 90 days, revenue estimates for Cytokinetics Inc (NASDAQ:CYTK) have increased from $0.02 billion to $0.08 billion for the full year 2025. For 2026, revenue estimates have declined from $0.17 billion to $0.14 billion. Earnings estimates for 2025 have declined from -$5.54 per share to -$5.65 per share, while for 2026, they have declined from -$5.25 per share to -$5.58 per share.
In the previous quarter of 2025-06-30, Cytokinetics Inc's (NASDAQ:CYTK) actual revenue was $0.07 billion, which beat analysts' revenue expectations of $0.00 billion by 2701.89%. Cytokinetics Inc's (NASDAQ:CYTK) actual earnings were -$1.12 per share, which beat analysts' earnings expectations of -$1.38 per share by 18.72%. After releasing the results, Cytokinetics Inc (NASDAQ:CYTK) was down by -3.23% in one day.
Based on the one-year price targets offered by 18 analysts, the average target price for Cytokinetics Inc (NASDAQ:CYTK) is $76.67 with a high estimate of $120.00 and a low estimate of $41.00. The average target implies an upside of 27.71% from the current price of $60.03.
Based on GuruFocus estimates, the estimated GF Value for Cytokinetics Inc (NASDAQ:CYTK) in one year is $327.75, suggesting an upside of 445.98% from the current price of $60.03.
Based on the consensus recommendation from 20 brokerage firms, Cytokinetics Inc's (NASDAQ:CYTK) average brokerage recommendation is currently 2.1, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.